A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor
You-Cheol Hwang (Hwang YC), Jae Hyeon Kim (Kim JH), Byung-Wan Lee (Lee BW), Woo Je Lee (Lee WJ)
Diabetes Metab J. 2019;43(6):898-905.   Published online 2019 Jun 14     DOI: https://doi.org/10.4093/dmj.2018.0257
Citations to this article as recorded by Crossref logo
Current Use and Complementary Value of Combining in Vivo Imaging Modalities to Understand the Renoprotective Effects of Sodium-Glucose Cotransporter-2 Inhibitors at a Tissue Level
Sjoukje van der Hoek, Jasper Stevens
Frontiers in Pharmacology.2022;[Epub]     CrossRef
Clinical and genetic determinants of urinary glucose excretion in patients with diabetes mellitus
Keisuke Monobe, Shinsuke Noso, Naru Babaya, Yoshihisa Hiromine, Yasunori Taketomo, Fumimaru Niwano, Sawa Yoshida, Sara Yasutake, Tatsuro Minohara, Yumiko Kawabata, Hiroshi Ikegami
Journal of Diabetes Investigation.2021; 12(5): 728.     CrossRef
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kyung-Soo Kim, Byung-Wan Lee
Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef